OncoMatch/Clinical Trials/NCT06354530
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Is NCT06354530 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies anlotinib for neoadjuvant therapy.
Treatment: anlotinib — The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma. The main question it aims to answer is: To evaluate the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma and to explore the optimal preoperative neoadjuvant treatment regimen for esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1-4AN+M0, CT3-4AN0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systematic antitumor treatment
No previous systematic antitumor treatment
Cannot have received: investigational drug
Have received any of the following treatments: any investigational drug
Cannot have received: anti-tumor
received anti-tumor
Cannot have received: live vaccine
received ... live vaccine
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5×10^9 / L; platelet ≥ 80×10^9 / L; hemoglobin ≥ 80×10^9 / L
Kidney function
within normal serum creatinine
Liver function
total bilirubin ≤ 1.5× upper limit of normal; ALT and glutamatergic aminase ≤ 2.5× upper limit of normal
absolute neutrophil count≥1.5×10^9 / L; platelet≥80×10^9 / L; hemoglobin≥80×10^9 / L; total bilirubin≤1.5×upper limit of normal; within normal serum creatinine; ALT and glutamatergic aminase≤2.5× upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06354530 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT1-4AN+M0 or CT3-4AN0M0 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages